# A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

> **NCT05473715** · PHASE4 · TERMINATED · sponsor: **Bayer** · enrollment: 3 (actual)

## Conditions studied

- Neovascular (Wet) Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept(BAY86-5321, Eylea)

## Key facts

- **NCT ID:** NCT05473715
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-25
- **Primary completion:** 2023-07-11
- **Final completion:** 2023-07-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated due to administrative reasons not related to efficacy or safety.
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473715, "A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05473715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*